Trotabresib

N/A

Report date: 2025/12/02 15:15:41
NME

Base Information

Drug NameTrotabresib
Drug Alias NameTROTACC-90010QC-5487BMS-986378
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsBrain metastasesSolid tumoursSmall Cell Lung Carcinoma +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenNetherlands +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesCelgene Corp
Inactive CompaniesBristol Myers Squibb SrlcompanyNorthwestern University
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsBrain metastasesSolid tumoursMeningeal Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG